Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
Drug Target Review
AUGUST 24, 2023
Her discoveries on the first-in-class RNA-based innate immune receptor agonist RGT100, built the foundation for the initiation of a Phase I clinical trial as well as the successful acquisition of Rigontec by MSD (known as Merck & Co. Shear forces induce ICAM-1 nanoclustering on endothelial cells that impact on T-cell migration.
Let's personalize your content